Purmorphamine (GMP)
Purmorphamine (GMP) is Purmorphamine produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM[1].
Product Specifications
CAS Number
483367-10-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Smo
Type
GMP Small Molecules
Related Pathways
Stem Cell/Wnt
Field of Research
Neurological Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/purmorphamine-gmp.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
N1(C2=CC=C(NC3=NC(OC4=CC=CC5=C4C=CC=C5)=NC6=C3N=CN6C7CCCCC7)C=C2)CCOCC1
Molecular Formula
C31H32N6O2
Molecular Weight
520.62
Precautions
H302, H315, H319, H335
References & Citations
[1]Karumbayaram S, et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells. 2009 Apr;27 (4) :806-11. |[2]Hu Y, et al. Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. J Neurosci Methods. 2016 Jun 15;266:42-9. |[3]Hua T, et al. Phenotypic, metabolic, and biogenesis properties of human stem cell-derived cerebellar spheroids. Sci Rep. 2022 Jul 27;12 (1) :12880. |[4]Sharma R, et al. 3D Bioprinting Pluripotent Stem Cell Derived Neural Tissues Using a Novel Fibrin Bioink Containing Drug Releasing Microspheres. Front Bioeng Biotechnol. 2020 Feb 11;8:57. |[5]Sundberg M, et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013 Aug;31 (8) :1548-62.
Shipping Conditions
Blue Ice
Storage Conditions
Keep sealed and protect from light, store at 2-8°C
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Citation 01
Life Sci. 2023 Sep 15:329:121990.|Adv Sci (Weinh) . 2025 May;12 (17) :e2411235.|Am J Physiol Cell Physiol. 2025 Oct 8.|Arthritis Res Ther. 2024 Jan 25;26 (1) :36.|Biochem Biophys Res Commun. 2021 Oct 15:574:1-7.|Burns Trauma. 2019 Sep 23;7:29.|Cancer Med. 2018 Nov;7 (11) :5704-5715.|Cell. 2025 Jun 26;188 (13) :3441-3458.e25.|Int J Mol Sci. 2024 Apr 9, 25 (8), 4138.|J Exp Clin Cancer Res. 2018 Nov 27;37 (1) :287. |J Hazard Mater. 2025 Oct 17:499:140149.|Med Oncol. 2021 Mar 17;38 (4) :41.|Mil Med Res. 2020 Nov 1;7 (1) :52.|Mil Med Res. 2020 Sep 6;7 (1) :42.|Mol Cell Toxicol. 2025 Oct 23.|Oncol Lett. 2019 Sep;18 (3) :3081-3091.|Patent. US20180263995A1.|Pharmacol Res. 2021 Mar:165:105460.|Res Sq. 2025 Apr 24.|Transl Neurodegener. 2024 Oct 29;13 (1) :53.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
AP53969PU-N 400 µL
Syntrophin (SNTB2) (Center) Rabbit Polyclonal Antibody
Sign In for Pricing
View Details 
